Back to Search
Start Over
Complement inhibitors are not useful in secondary hemolytic uremic syndromes.
- Source :
-
Kidney international [Kidney Int] 2019 Oct; Vol. 96 (4), pp. 829-833. - Publication Year :
- 2019
- Subjects :
- Antibodies, Monoclonal, Humanized economics
Antibodies, Monoclonal, Humanized pharmacology
Complement Activation drug effects
Complement Activation immunology
Complement Inactivating Agents economics
Complement Inactivating Agents pharmacology
Complement System Proteins immunology
Cost-Benefit Analysis
Early Termination of Clinical Trials
Hemolytic-Uremic Syndrome economics
Hemolytic-Uremic Syndrome immunology
Hemolytic-Uremic Syndrome microbiology
Humans
Patient Outcome Assessment
Randomized Controlled Trials as Topic
Standard of Care economics
Treatment Outcome
Antibodies, Monoclonal, Humanized therapeutic use
Complement Inactivating Agents therapeutic use
Complement System Proteins metabolism
Hemolytic-Uremic Syndrome drug therapy
Shiga-Toxigenic Escherichia coli immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1523-1755
- Volume :
- 96
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Kidney international
- Publication Type :
- Academic Journal
- Accession number :
- 31543154
- Full Text :
- https://doi.org/10.1016/j.kint.2019.08.001